UC San Diego scientists have created new brain maps featuring unprecedented detail. The insights provided by the new maps are helping answer questions about blood supply and how more active parts of the brain are kept nourished versus less demanding areas.
A comprehensive review of the current CRISPR clinical trials landscape, covering progress on blood disorders, cancers, eye disease, chronic infection, rare protein-folding disease, and future prospects.
In presentations at the American Association for the Advancement of Science’s annual meeting, researchers argued that mathematics can help explain and predict those breakdowns, potentially offering new ways of treating the systems to prevent or fix them when things go wrong.
At 31 weeks and 5 days pregnant with identical twins, Amberlyn Smith went to her bi-weekly ultrasound feeling confident. Just two weeks prior, both of the twins had grown appropriately and screening tests came back normal. But that day, Dec. 23, there was a clear discrepancy in their size, as well as a notable abnormality in their blood flow. Smith was immediately sent to see an intervention specialist with UTHealth at Children’s Memorial Hermann Hospital, where she emergently delivered the twins the next morning, on Christmas Eve.
Utah researchers report significant new insights into the development of blood cancers. Comparing DNA data in people with and without blood disorders, the researchers discovered genetic mutations in about 2% of the presumably healthy participants that were identical to those frequently observed in the cancer patients. These findings provide new clues about mutations that may initiate cancer development and those that may help cancer progress.
There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States. A new preliminary study has found that they are not associated with an increased risk of intracerebral hemorrhage, the deadliest kind of stroke. The preliminary study released today, February 25, 2021, will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
Researchers have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give doctors an opportunity to intervene and prevent permanent damage, potentially using an existing medication.
Scientists at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified the specialized environment, known as a niche, in the bone marrow where new bone and immune cells are produced. The study, published in Nature, also shows that movement-induced stimulation is required for the maintenance of this niche, as well as the bone and immune-forming cells that it contains. Together, these findings identify a new way that exercise strengthens bones and immune function.
A complete blood count can help ascertain the health of a patient and typically includes an estimate of the hemoglobin concentration, which can indicate several conditions, including anemia, polycythemia, and pulmonary fibrosis. In AIP Advances, researchers describe a new AI-powered imaging-based tool to estimate hemoglobin levels. The setup was developed in conjunction with a microfluidic chip and an AI-powered automated microscope that was designed for deriving the total as well as differential counts of blood cells.
A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans.
A potentially dangerous side effect of testosterone therapy for transgender men is an increase in red blood cells that can raise the risk of blood clots, heart attack or stroke, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
The National Institutes of Health (NIH) has awarded a $2.1 million, four-year research grant to Anirban Sen Gupta at Case Western Reserve University in Cleveland, Ohio, and collaborators at the University of Michigan and University of North Carolina, to advance the design of artificial platelets that can promote and stabilize clots to stop bleeding.
Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.
The research team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results.
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation.
A team of researchers from the Case Western Reserve University School of Medicine, Case School of Engineering and Louis Stokes Cleveland VA Medical Center is developing a blood-test device as an early warning system to help prevent pressure injuries.
A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February.
A new paper published online in the Annals of the American Thoracic Society describes a “virtual” recovery program for sepsis patients that may also help post-COVID-19 patients and survivors of other serious illnesses.
Two new blood filters, proven to safely and quickly remove a range of pathogens, including COVID-19, from blood during pre-clinical testing, will now be further evaluated to determine their efficacy in patients under a new cooperative agreement between the Uniformed Services University (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF).
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Case Western Reserve University researchers who developed a portable sensor to assess the clotting ability of a person’s blood are working with the U.S. Navy to develop a rugged version of the device to detect problems with blood coagulation in cases of traumatic injury and preserve critical blood supplies.
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma.
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers.
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences.
Irvine, Calif., Feb. 1, 2021 — Researchers from the University of California, Irvine and the University of Minnesota have found that an enriched diet and companionship can reduce pain in mice with sickle cell disease by increasing serotonin. They also discovered that duloxetine, an antidepressant that boosts serotonin levels, could be an alternative to opioids in treating chronic pain.
A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.
A Cornell-led collaboration has developed a noninvasive blood test that uses cell-free DNA to gauge the damage that COVID-19 inflicts on cells, tissues and organs, and could help aid in the development of new therapies.
Scientists from the National University of Singapore have discovered how a protein called Tip60 plays a vital role in the renewal of blood cells in the body. Without it, the stem cells that make new blood suffer catastrophic damage. This discovery could lead to better treatments for life-threatening blood-related diseases like leukemia.
Dr. Richi Gill, MD, is back at work, able to enjoy time with his family in the evening and get a good night's sleep, thanks to research.
Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer risk for both astronauts and people on Earth.
Investigadores y colaboradores de Mayo Clinic descubrieron una asociación entre la administración de plasma convaleciente con alta carga de anticuerpos y menores tasas de mortalidad en pacientes internados con COVID-19 sin respirador.
El 4 de febrero de 2021 es el Día Mundial contra el Cáncer y sirve para resaltar cómo podemos todos ayudar a reducir el peso mundial del cáncer. En el año 2018, hubo 17 millones de casos nuevos de cáncer y 9,5 millones de muertes por cáncer en todo el mundo.
Blood draws are no fun.They hurt. Veins can burst, or even roll — like they’re trying to avoid the needle, too.Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal a viral or bacterial infection, such as SARS-CoV-2, the virus responsible for COVID-19, or cytokines indicative of inflammation seen in conditions such as rheumatoid arthritis and sepsis.
Clinical trial finds that full-dose treatment with blood thinner reduces need for vital organ support in ICUs in moderately ill hospitalized COVID-19 patients.
University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the DNA of patients’ blood cells.
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
G6PD deficiency affects about 400M people worldwide and can pose serious health risks. Uncovering the causes of the most severe cases could finally lead to treatments.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Tuesday.
Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies.
Dr. Marc Suchard, of the UCLA Fielding School of Public Health, co-led international research team looking at two widely used types of blood pressure drugs.
Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.
This is the first study to demonstrate that there is no difference in blood clots when transgender women remain on estrogen hormone therapy for gender affirming surgery. Because both estrogen therapy and surgery can increase a person’s risk of blood clots, experts had long suggested that transgender women stop taking estrogen when undergoing gender affirming surgery. However, there was previously no published data on the blood clot risk specific to transgender women undergoing surgery.
You have the power to save lives today. January is National Blood Donation Month. Learn the benefits of donating—and how local organizations ensure donation is safe—in this week’s Penn State Health Medical Minute.
Wistar scientists discovered that EGR1 inhibits expression of pro-inflammatory genes in macrophages. The discovery expands the understanding of how macrophages are set off and deactivated in the inflammatory process, which is critical in many normal and pathological conditions.
In three recent publications in Molecular Psychiatry, Brain and JAMA Neurology researchers from the University of Gothenburg provide convincing evidence that an in-house developed blood test for Alzheimer's disease can detect the disease early and track its course, which has major implications for a potential use in clinical practice and treatment trials.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right